Medtronic's neurosurgery guidance system receives US FDA clearance
Insight Weekly: Unease roils markets; US likely to slip into recession; firms' cash ratios fall
Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap
Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future
Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch
The U.S. Food and Drug Administration has cleared Medtronic PLC's Stealth Autoguide system, a robotic surgery platform that provides positioning assistance during neurosurgical procedures.
Medtronic's robotic platform helps surgeons prepare and carry out precise procedures as part of the company's Surgical Synergy platform.
Dublin-based Medtronic develops device-based medical therapies.